T-FITNESS Fine-tuning T Cell Networks of Exhaustion by Synthetic Sensors
- Coordinator
- Stiftung Leibniz-Institut Fur Immuntherapie, Germany
- Runs
- 1 September 2022 to 30 April 2027
- Status
- Running
- EU funding
- €4.4m
- Total cost
- €4.4m
- Partners
- 8 organisations in 6 countries
- Type
- European Innovation Council
- Grant agreement
- 101070740
What the project is doing
In the project's own words, from its summary on CORDIS.
Cell and gene therapies offer a massive paradigm shift from current treatment options and hold the potential to cure previously untreatable diseases. Naturally-occurring and genetically modified T cells with chimeric antigen (CAR) or T cell receptors (TCR) have demonstrated remarkable curative capacities against advanced hematologic malignancies but have shown limited efficacy in treating solid tumors. Major barriers hindering the full antitumor potential of T cells are the immunosuppressive signals and persisting antigenic stimuli within the tumor microenvironment that inexorably push T cells into a highly dysfunctional state called “exhaustion”.
Herein, we propose a groundbreaking technology, T-FITNESS, which will enable antitumor T cells to become refractory to exhaustion. At the core of the platform are microRNA (miRNA)-based synthetic logic circuits capable of rewiring the transcriptional networks orchestrating T cell exhaustion. By harnessing the power of CRISPR/Cas genome editing, we will integrate sensors of miRNAs upregulated in exhausted cells into untranslated regions of one or more transcription factors driving T cell exhaustion, to enable their fine-tuned downregulation.
We will validate the reprogramming efficacy of T-FITNESS by performing extensive functional analyses in vitro and in vivo and advance the best circuits towards the clinic by developing an automated cGMP-compliant manufacturing process for point-of-care production of T-FITNESS-edited CAR-T cells. To develop this innovative platform, we will bring together a multidisciplinary consortium of academic and industry partners that combine their unique expertise in T cell therapy and immunology, synthetic biology, genome editing, cGMP manufacturing, bioinformatics, and communication.
Easily integrable within CAR-T, TCR-T, and tumor-infiltrating lymphocyte (TIL) platforms, T-FITNESS will unleash the curative potential of T cell therapy for the benefit of an ever-growing number of cancer patients.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stiftung Leibniz-Institut Fur Immuntherapie | Regensburg | Germany | Coordinator |
| Eidgenoessische Technische Hochschule Zuerich | Zuerich | Switzerland | Associatedpartner |
| Miltenyi Biotec BV & Co Kg | Bergisch Gladbach | Germany | Participant |
| Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer | Barcelona | Spain | Participant |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Fondazione Istituto Italiano Di Tecnologia | Genova | Italy | Participant |
| Innovation Acta SRL | Siena | Italy | Participant |
| Kemijski Institut | Ljubljana | Slovenia | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI